Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Autoimmune Disease Diagnostics Market by Type (Localized Autoimmune Disease Diagnostic, Systemic Autoimmune Disease Diagnostic), by Product (Drugs, Therapeutic Monitoring Equipment, Diagnostic Equipment) and by Technology (Bridge Therapy, Disease-modifying Antirheumatic Drugs (DMARD), Topical Therapy, Phototherapy, Helminthic Therapy, Recombinant Technology): Global Opportunity Analysis and Industry Forecast, 2023-2032

A02365

Pages: NA

Charts: NA

Tables: NA

Autoimmune diseases refer to a bodys abnormal immune response leading to production of antibodies that attack own cells and tissues, causing deterioration and destruction of healthy tissues. There are almost 80 types of autoimmune diseases prevailing worldwide including systemic lupus erythematosus or rheumatoid arthritis. According to the estimation by American Autoimmune Related Diseases Association (AARDA), autoimmune disease affects up to 50 million Americans and 75% of them are females. The tests used to diagnose the autoimmune disease include auto antibody test, antinuclear antibody test, complete blood count, C-reactive protein, and erythrocyte sedimentation rate.

The global autoimmune disease diagnostics market is driven by improved laboratory techniques and automation, growth in public awareness for autoimmune disorders, rise in partnerships between physicians and clinical laboratories, increase in incidence of diseases such as rheumatoid arthritis and Graves and Hashimoto's Thyroid Disease. However, high frequency of false positive results and slow turnaround time for diagnostic test results restrain the market growth. Rapid technological advancements in medical field such as novel biomarkers, rise in healthcare expenditure, development of the emerging markets, and favorable government initiatives is expected to offer lucrative opportunities for the growth of the market.

This global market is segmented on the basis of type, product, service, technology, and region. Based on type, it is bifurcated into localized autoimmune disease diagnostic and systemic autoimmune disease diagnostic. Based on product, it is divided into drugs, therapeutic & monitoring equipment, and diagnostic equipment. Based on technology, it is divided into bridge therapy, disease-modifying antirheumatic drugs (DMARD), topical therapy, phototherapy, helminthic therapy, and recombinant technology. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key players operating in this market are AstraZeneca, F. Hoffmann-La Roche, Novartis AG, Pfizer Inc., Sanofi-aventis, Abbott Laboratories, Beckman Coulter Inc., Inova Diagnostics Inc., Bio-Rad Laboratories Inc., and Hemagen Diagnostics Inc.

Key Benefits

  • The study provides an in-depth analysis of the global autoimmune disease diagnostic market along with current trends and future estimations to elucidate the imminent investment pockets.
  • It presents a quantitative analysis to enable the stakeholders to capitalize on the prevailing market opportunities.
  • Extensive analysis of the market by product assists to understand the various forms of autoimmune disease diagnostic available.
  • Key players are profiled and their strategies are analyzed thoroughly to predict the competitive outlook of the market.

 Key Market Segments

  • By Type
    • Localized Autoimmune Disease Diagnostic
    • Systemic Autoimmune Disease Diagnostic
  • By Product
    • Drugs
    • Therapeutic & Monitoring Equipment
    • Diagnostic Equipment
  • By Technology
    • Bridge Therapy
    • Disease-modifying Antirheumatic Drugs (DMARD)
    • Topical Therapy
    • Phototherapy
    • Helminthic Therapy
    • Recombinant Technology
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA

 
Key Market Players

  • Inova Diagnostics Inc.
  • Abbott Laboratories
  • AstraZeneca
  • Beckman Coulter Inc.
  • Pfizer Inc.
  • Sanofi-Aventis
  • F. Hoffmann-La Roche
  • Novartis AG
  • Hemagen Diagnostics Inc.
  • Bio-Rad Laboratories Inc.

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: AUTOIMMUNE DISEASE DIAGNOSTICS MARKET, BY TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Type

    • 4.2. Localized Autoimmune Disease Diagnostic

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Systemic Autoimmune Disease Diagnostic

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

  • CHAPTER 5: AUTOIMMUNE DISEASE DIAGNOSTICS MARKET, BY PRODUCT

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Product

    • 5.2. Drugs

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Therapeutic And Monitoring Equipment

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Diagnostic Equipment

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

  • CHAPTER 6: AUTOIMMUNE DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Technology

    • 6.2. Bridge Therapy

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Disease-modifying Antirheumatic Drugs (DMARD)

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Topical Therapy

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

    • 6.5. Phototherapy

      • 6.5.1. Key Market Trends, Growth Factors and Opportunities

      • 6.5.2. Market Size and Forecast, By Region

      • 6.5.3. Market Share Analysis, By Country

    • 6.6. Helminthic Therapy

      • 6.6.1. Key Market Trends, Growth Factors and Opportunities

      • 6.6.2. Market Size and Forecast, By Region

      • 6.6.3. Market Share Analysis, By Country

    • 6.7. Recombinant Technology

      • 6.7.1. Key Market Trends, Growth Factors and Opportunities

      • 6.7.2. Market Size and Forecast, By Region

      • 6.7.3. Market Share Analysis, By Country

  • CHAPTER 7: AUTOIMMUNE DISEASE DIAGNOSTICS MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Type

      • 7.2.3. Market Size and Forecast, By Product

      • 7.2.4. Market Size and Forecast, By Technology

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S. Autoimmune Disease Diagnostics Market

        • 7.2.6.1. Market Size and Forecast, By Type
        • 7.2.6.2. Market Size and Forecast, By Product
        • 7.2.6.3. Market Size and Forecast, By Technology

      • 7.2.7. Canada Autoimmune Disease Diagnostics Market

        • 7.2.7.1. Market Size and Forecast, By Type
        • 7.2.7.2. Market Size and Forecast, By Product
        • 7.2.7.3. Market Size and Forecast, By Technology

      • 7.2.8. Mexico Autoimmune Disease Diagnostics Market

        • 7.2.8.1. Market Size and Forecast, By Type
        • 7.2.8.2. Market Size and Forecast, By Product
        • 7.2.8.3. Market Size and Forecast, By Technology

    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Type

      • 7.3.3. Market Size and Forecast, By Product

      • 7.3.4. Market Size and Forecast, By Technology

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France Autoimmune Disease Diagnostics Market

        • 7.3.6.1. Market Size and Forecast, By Type
        • 7.3.6.2. Market Size and Forecast, By Product
        • 7.3.6.3. Market Size and Forecast, By Technology

      • 7.3.7. Germany Autoimmune Disease Diagnostics Market

        • 7.3.7.1. Market Size and Forecast, By Type
        • 7.3.7.2. Market Size and Forecast, By Product
        • 7.3.7.3. Market Size and Forecast, By Technology

      • 7.3.8. Italy Autoimmune Disease Diagnostics Market

        • 7.3.8.1. Market Size and Forecast, By Type
        • 7.3.8.2. Market Size and Forecast, By Product
        • 7.3.8.3. Market Size and Forecast, By Technology

      • 7.3.9. Spain Autoimmune Disease Diagnostics Market

        • 7.3.9.1. Market Size and Forecast, By Type
        • 7.3.9.2. Market Size and Forecast, By Product
        • 7.3.9.3. Market Size and Forecast, By Technology

      • 7.3.10. UK Autoimmune Disease Diagnostics Market

        • 7.3.10.1. Market Size and Forecast, By Type
        • 7.3.10.2. Market Size and Forecast, By Product
        • 7.3.10.3. Market Size and Forecast, By Technology

      • 7.3.11. Russia Autoimmune Disease Diagnostics Market

        • 7.3.11.1. Market Size and Forecast, By Type
        • 7.3.11.2. Market Size and Forecast, By Product
        • 7.3.11.3. Market Size and Forecast, By Technology

      • 7.3.12. Rest Of Europe Autoimmune Disease Diagnostics Market

        • 7.3.12.1. Market Size and Forecast, By Type
        • 7.3.12.2. Market Size and Forecast, By Product
        • 7.3.12.3. Market Size and Forecast, By Technology

    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Type

      • 7.4.3. Market Size and Forecast, By Product

      • 7.4.4. Market Size and Forecast, By Technology

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China Autoimmune Disease Diagnostics Market

        • 7.4.6.1. Market Size and Forecast, By Type
        • 7.4.6.2. Market Size and Forecast, By Product
        • 7.4.6.3. Market Size and Forecast, By Technology

      • 7.4.7. Japan Autoimmune Disease Diagnostics Market

        • 7.4.7.1. Market Size and Forecast, By Type
        • 7.4.7.2. Market Size and Forecast, By Product
        • 7.4.7.3. Market Size and Forecast, By Technology

      • 7.4.8. India Autoimmune Disease Diagnostics Market

        • 7.4.8.1. Market Size and Forecast, By Type
        • 7.4.8.2. Market Size and Forecast, By Product
        • 7.4.8.3. Market Size and Forecast, By Technology

      • 7.4.9. South Korea Autoimmune Disease Diagnostics Market

        • 7.4.9.1. Market Size and Forecast, By Type
        • 7.4.9.2. Market Size and Forecast, By Product
        • 7.4.9.3. Market Size and Forecast, By Technology

      • 7.4.10. Australia Autoimmune Disease Diagnostics Market

        • 7.4.10.1. Market Size and Forecast, By Type
        • 7.4.10.2. Market Size and Forecast, By Product
        • 7.4.10.3. Market Size and Forecast, By Technology

      • 7.4.11. Thailand Autoimmune Disease Diagnostics Market

        • 7.4.11.1. Market Size and Forecast, By Type
        • 7.4.11.2. Market Size and Forecast, By Product
        • 7.4.11.3. Market Size and Forecast, By Technology

      • 7.4.12. Malaysia Autoimmune Disease Diagnostics Market

        • 7.4.12.1. Market Size and Forecast, By Type
        • 7.4.12.2. Market Size and Forecast, By Product
        • 7.4.12.3. Market Size and Forecast, By Technology

      • 7.4.13. Indonesia Autoimmune Disease Diagnostics Market

        • 7.4.13.1. Market Size and Forecast, By Type
        • 7.4.13.2. Market Size and Forecast, By Product
        • 7.4.13.3. Market Size and Forecast, By Technology

      • 7.4.14. Rest of Asia Pacific Autoimmune Disease Diagnostics Market

        • 7.4.14.1. Market Size and Forecast, By Type
        • 7.4.14.2. Market Size and Forecast, By Product
        • 7.4.14.3. Market Size and Forecast, By Technology

    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Type

      • 7.5.3. Market Size and Forecast, By Product

      • 7.5.4. Market Size and Forecast, By Technology

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil Autoimmune Disease Diagnostics Market

        • 7.5.6.1. Market Size and Forecast, By Type
        • 7.5.6.2. Market Size and Forecast, By Product
        • 7.5.6.3. Market Size and Forecast, By Technology

      • 7.5.7. South Africa Autoimmune Disease Diagnostics Market

        • 7.5.7.1. Market Size and Forecast, By Type
        • 7.5.7.2. Market Size and Forecast, By Product
        • 7.5.7.3. Market Size and Forecast, By Technology

      • 7.5.8. Saudi Arabia Autoimmune Disease Diagnostics Market

        • 7.5.8.1. Market Size and Forecast, By Type
        • 7.5.8.2. Market Size and Forecast, By Product
        • 7.5.8.3. Market Size and Forecast, By Technology

      • 7.5.9. UAE Autoimmune Disease Diagnostics Market

        • 7.5.9.1. Market Size and Forecast, By Type
        • 7.5.9.2. Market Size and Forecast, By Product
        • 7.5.9.3. Market Size and Forecast, By Technology

      • 7.5.10. Argentina Autoimmune Disease Diagnostics Market

        • 7.5.10.1. Market Size and Forecast, By Type
        • 7.5.10.2. Market Size and Forecast, By Product
        • 7.5.10.3. Market Size and Forecast, By Technology

      • 7.5.11. Rest of LAMEA Autoimmune Disease Diagnostics Market

        • 7.5.11.1. Market Size and Forecast, By Type
        • 7.5.11.2. Market Size and Forecast, By Product
        • 7.5.11.3. Market Size and Forecast, By Technology

  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning, 2024

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. AstraZeneca

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. F. Hoffmann-La Roche

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. Novartis AG

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. Pfizer Inc.

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. Sanofi-Aventis

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. Abbott Laboratories

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. Beckman Coulter Inc.

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. Inova Diagnostics Inc.

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. Bio-Rad Laboratories Inc.

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

    • 9.10. Hemagen Diagnostics Inc.

      • 9.10.1. Company Overview

      • 9.10.2. Key Executives

      • 9.10.3. Company Snapshot

      • 9.10.4. Operating Business Segments

      • 9.10.5. Product Portfolio

      • 9.10.6. Business Performance

      • 9.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET FOR LOCALIZED AUTOIMMUNE DISEASE DIAGNOSTIC, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET FOR SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTIC, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET FOR DRUGS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET FOR THERAPEUTIC AND MONITORING EQUIPMENT, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTIC EQUIPMENT, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET FOR BRIDGE THERAPY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET FOR DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARD), BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET FOR TOPICAL THERAPY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET FOR PHOTOTHERAPY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 13. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET FOR HELMINTHIC THERAPY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 14. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET FOR RECOMBINANT TECHNOLOGY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 15. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 16. NORTH AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 17. NORTH AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 18. NORTH AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 19. NORTH AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 20. U.S. AUTOIMMUNE DISEASE DIAGNOSTICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 21. U.S. AUTOIMMUNE DISEASE DIAGNOSTICS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 22. U.S. AUTOIMMUNE DISEASE DIAGNOSTICS, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 23. CANADA AUTOIMMUNE DISEASE DIAGNOSTICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 24. CANADA AUTOIMMUNE DISEASE DIAGNOSTICS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 25. CANADA AUTOIMMUNE DISEASE DIAGNOSTICS, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 26. MEXICO AUTOIMMUNE DISEASE DIAGNOSTICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 27. MEXICO AUTOIMMUNE DISEASE DIAGNOSTICS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 28. MEXICO AUTOIMMUNE DISEASE DIAGNOSTICS, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 29. EUROPE AUTOIMMUNE DISEASE DIAGNOSTICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 30. EUROPE AUTOIMMUNE DISEASE DIAGNOSTICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 31. EUROPE AUTOIMMUNE DISEASE DIAGNOSTICS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 32. EUROPE AUTOIMMUNE DISEASE DIAGNOSTICS, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 33. FRANCE AUTOIMMUNE DISEASE DIAGNOSTICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 34. FRANCE AUTOIMMUNE DISEASE DIAGNOSTICS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 35. FRANCE AUTOIMMUNE DISEASE DIAGNOSTICS, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 36. GERMANY AUTOIMMUNE DISEASE DIAGNOSTICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 37. GERMANY AUTOIMMUNE DISEASE DIAGNOSTICS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 38. GERMANY AUTOIMMUNE DISEASE DIAGNOSTICS, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 39. ITALY AUTOIMMUNE DISEASE DIAGNOSTICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 40. ITALY AUTOIMMUNE DISEASE DIAGNOSTICS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 41. ITALY AUTOIMMUNE DISEASE DIAGNOSTICS, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 42. SPAIN AUTOIMMUNE DISEASE DIAGNOSTICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 43. SPAIN AUTOIMMUNE DISEASE DIAGNOSTICS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 44. SPAIN AUTOIMMUNE DISEASE DIAGNOSTICS, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 45. UK AUTOIMMUNE DISEASE DIAGNOSTICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 46. UK AUTOIMMUNE DISEASE DIAGNOSTICS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 47. UK AUTOIMMUNE DISEASE DIAGNOSTICS, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 48. RUSSIA AUTOIMMUNE DISEASE DIAGNOSTICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 49. RUSSIA AUTOIMMUNE DISEASE DIAGNOSTICS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 50. RUSSIA AUTOIMMUNE DISEASE DIAGNOSTICS, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 51. REST OF EUROPE AUTOIMMUNE DISEASE DIAGNOSTICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 52. REST OF EUROPE AUTOIMMUNE DISEASE DIAGNOSTICS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 53. REST OF EUROPE AUTOIMMUNE DISEASE DIAGNOSTICS, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 54. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 55. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 56. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 57. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 58. CHINA AUTOIMMUNE DISEASE DIAGNOSTICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 59. CHINA AUTOIMMUNE DISEASE DIAGNOSTICS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 60. CHINA AUTOIMMUNE DISEASE DIAGNOSTICS, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 61. JAPAN AUTOIMMUNE DISEASE DIAGNOSTICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 62. JAPAN AUTOIMMUNE DISEASE DIAGNOSTICS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 63. JAPAN AUTOIMMUNE DISEASE DIAGNOSTICS, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 64. INDIA AUTOIMMUNE DISEASE DIAGNOSTICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 65. INDIA AUTOIMMUNE DISEASE DIAGNOSTICS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 66. INDIA AUTOIMMUNE DISEASE DIAGNOSTICS, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 67. SOUTH KOREA AUTOIMMUNE DISEASE DIAGNOSTICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 68. SOUTH KOREA AUTOIMMUNE DISEASE DIAGNOSTICS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 69. SOUTH KOREA AUTOIMMUNE DISEASE DIAGNOSTICS, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 70. AUSTRALIA AUTOIMMUNE DISEASE DIAGNOSTICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 71. AUSTRALIA AUTOIMMUNE DISEASE DIAGNOSTICS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 72. AUSTRALIA AUTOIMMUNE DISEASE DIAGNOSTICS, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 73. THAILAND AUTOIMMUNE DISEASE DIAGNOSTICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 74. THAILAND AUTOIMMUNE DISEASE DIAGNOSTICS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 75. THAILAND AUTOIMMUNE DISEASE DIAGNOSTICS, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 76. MALAYSIA AUTOIMMUNE DISEASE DIAGNOSTICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 77. MALAYSIA AUTOIMMUNE DISEASE DIAGNOSTICS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 78. MALAYSIA AUTOIMMUNE DISEASE DIAGNOSTICS, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 79. INDONESIA AUTOIMMUNE DISEASE DIAGNOSTICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 80. INDONESIA AUTOIMMUNE DISEASE DIAGNOSTICS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 81. INDONESIA AUTOIMMUNE DISEASE DIAGNOSTICS, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 82. REST OF ASIA PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 83. REST OF ASIA PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 84. REST OF ASIA PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 85. LAMEA AUTOIMMUNE DISEASE DIAGNOSTICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 86. LAMEA AUTOIMMUNE DISEASE DIAGNOSTICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 87. LAMEA AUTOIMMUNE DISEASE DIAGNOSTICS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 88. LAMEA AUTOIMMUNE DISEASE DIAGNOSTICS, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 89. BRAZIL AUTOIMMUNE DISEASE DIAGNOSTICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 90. BRAZIL AUTOIMMUNE DISEASE DIAGNOSTICS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 91. BRAZIL AUTOIMMUNE DISEASE DIAGNOSTICS, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 92. SOUTH AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 93. SOUTH AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 94. SOUTH AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 95. SAUDI ARABIA AUTOIMMUNE DISEASE DIAGNOSTICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 96. SAUDI ARABIA AUTOIMMUNE DISEASE DIAGNOSTICS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 97. SAUDI ARABIA AUTOIMMUNE DISEASE DIAGNOSTICS, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 98. UAE AUTOIMMUNE DISEASE DIAGNOSTICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 99. UAE AUTOIMMUNE DISEASE DIAGNOSTICS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 100. UAE AUTOIMMUNE DISEASE DIAGNOSTICS, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 101. ARGENTINA AUTOIMMUNE DISEASE DIAGNOSTICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 102. ARGENTINA AUTOIMMUNE DISEASE DIAGNOSTICS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 103. ARGENTINA AUTOIMMUNE DISEASE DIAGNOSTICS, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 104. REST OF LAMEA AUTOIMMUNE DISEASE DIAGNOSTICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 105. REST OF LAMEA AUTOIMMUNE DISEASE DIAGNOSTICS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 106. REST OF LAMEA AUTOIMMUNE DISEASE DIAGNOSTICS, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 107. ASTRAZENECA: KEY EXECUTIVES
  • TABLE 108. ASTRAZENECA: COMPANY SNAPSHOT
  • TABLE 109. ASTRAZENECA: OPERATING SEGMENTS
  • TABLE 110. ASTRAZENECA: PRODUCT PORTFOLIO
  • TABLE 111. ASTRAZENECA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 112. F. HOFFMANN-LA ROCHE: KEY EXECUTIVES
  • TABLE 113. F. HOFFMANN-LA ROCHE: COMPANY SNAPSHOT
  • TABLE 114. F. HOFFMANN-LA ROCHE: OPERATING SEGMENTS
  • TABLE 115. F. HOFFMANN-LA ROCHE: PRODUCT PORTFOLIO
  • TABLE 116. F. HOFFMANN-LA ROCHE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 117. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 118. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 119. NOVARTIS AG: OPERATING SEGMENTS
  • TABLE 120. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 121. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 122. PFIZER INC.: KEY EXECUTIVES
  • TABLE 123. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 124. PFIZER INC.: OPERATING SEGMENTS
  • TABLE 125. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 126. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 127. SANOFI-AVENTIS: KEY EXECUTIVES
  • TABLE 128. SANOFI-AVENTIS: COMPANY SNAPSHOT
  • TABLE 129. SANOFI-AVENTIS: OPERATING SEGMENTS
  • TABLE 130. SANOFI-AVENTIS: PRODUCT PORTFOLIO
  • TABLE 131. SANOFI-AVENTIS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 132. ABBOTT LABORATORIES: KEY EXECUTIVES
  • TABLE 133. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 134. ABBOTT LABORATORIES: OPERATING SEGMENTS
  • TABLE 135. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 136. ABBOTT LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 137. BECKMAN COULTER INC.: KEY EXECUTIVES
  • TABLE 138. BECKMAN COULTER INC.: COMPANY SNAPSHOT
  • TABLE 139. BECKMAN COULTER INC.: OPERATING SEGMENTS
  • TABLE 140. BECKMAN COULTER INC.: PRODUCT PORTFOLIO
  • TABLE 141. BECKMAN COULTER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 142. INOVA DIAGNOSTICS INC.: KEY EXECUTIVES
  • TABLE 143. INOVA DIAGNOSTICS INC.: COMPANY SNAPSHOT
  • TABLE 144. INOVA DIAGNOSTICS INC.: OPERATING SEGMENTS
  • TABLE 145. INOVA DIAGNOSTICS INC.: PRODUCT PORTFOLIO
  • TABLE 146. INOVA DIAGNOSTICS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 147. BIO-RAD LABORATORIES INC.: KEY EXECUTIVES
  • TABLE 148. BIO-RAD LABORATORIES INC.: COMPANY SNAPSHOT
  • TABLE 149. BIO-RAD LABORATORIES INC.: OPERATING SEGMENTS
  • TABLE 150. BIO-RAD LABORATORIES INC.: PRODUCT PORTFOLIO
  • TABLE 151. BIO-RAD LABORATORIES INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 152. HEMAGEN DIAGNOSTICS INC.: KEY EXECUTIVES
  • TABLE 153. HEMAGEN DIAGNOSTICS INC.: COMPANY SNAPSHOT
  • TABLE 154. HEMAGEN DIAGNOSTICS INC.: OPERATING SEGMENTS
  • TABLE 155. HEMAGEN DIAGNOSTICS INC.: PRODUCT PORTFOLIO
  • TABLE 156. HEMAGEN DIAGNOSTICS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SEGMENTATION
  • FIGURE 2. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET
  • FIGURE 3. SEGMENTATION AUTOIMMUNE DISEASE DIAGNOSTICS MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALAUTOIMMUNE DISEASE DIAGNOSTICS MARKET
  • FIGURE 11. AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SEGMENTATION, BY BY TYPE
  • FIGURE 12. AUTOIMMUNE DISEASE DIAGNOSTICS MARKET FOR LOCALIZED AUTOIMMUNE DISEASE DIAGNOSTIC, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. AUTOIMMUNE DISEASE DIAGNOSTICS MARKET FOR SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTIC, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SEGMENTATION, BY BY PRODUCT
  • FIGURE 15. AUTOIMMUNE DISEASE DIAGNOSTICS MARKET FOR DRUGS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. AUTOIMMUNE DISEASE DIAGNOSTICS MARKET FOR THERAPEUTIC AND MONITORING EQUIPMENT, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. AUTOIMMUNE DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTIC EQUIPMENT, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SEGMENTATION, BY BY TECHNOLOGY
  • FIGURE 19. AUTOIMMUNE DISEASE DIAGNOSTICS MARKET FOR BRIDGE THERAPY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 20. AUTOIMMUNE DISEASE DIAGNOSTICS MARKET FOR DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARD), BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 21. AUTOIMMUNE DISEASE DIAGNOSTICS MARKET FOR TOPICAL THERAPY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 22. AUTOIMMUNE DISEASE DIAGNOSTICS MARKET FOR PHOTOTHERAPY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 23. AUTOIMMUNE DISEASE DIAGNOSTICS MARKET FOR HELMINTHIC THERAPY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 24. AUTOIMMUNE DISEASE DIAGNOSTICS MARKET FOR RECOMBINANT TECHNOLOGY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 25. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 26. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 27. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 28. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 29. COMPETITIVE DASHBOARD
  • FIGURE 30. COMPETITIVE HEATMAP: AUTOIMMUNE DISEASE DIAGNOSTICS MARKET
  • FIGURE 31. TOP PLAYER POSITIONING, 2024
  • FIGURE 32. ASTRAZENECA: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 33. ASTRAZENECA: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 34. ASTRAZENECA: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 35. F. HOFFMANN-LA ROCHE: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 36. F. HOFFMANN-LA ROCHE: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 37. F. HOFFMANN-LA ROCHE: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 38. NOVARTIS AG: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 39. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 40. NOVARTIS AG: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 41. PFIZER INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 42. PFIZER INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 43. PFIZER INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 44. SANOFI-AVENTIS: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 45. SANOFI-AVENTIS: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 46. SANOFI-AVENTIS: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 47. ABBOTT LABORATORIES: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 48. ABBOTT LABORATORIES: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 49. ABBOTT LABORATORIES: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 50. BECKMAN COULTER INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 51. BECKMAN COULTER INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 52. BECKMAN COULTER INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 53. INOVA DIAGNOSTICS INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 54. INOVA DIAGNOSTICS INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 55. INOVA DIAGNOSTICS INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 56. BIO-RAD LABORATORIES INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 57. BIO-RAD LABORATORIES INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 58. BIO-RAD LABORATORIES INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 59. HEMAGEN DIAGNOSTICS INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 60. HEMAGEN DIAGNOSTICS INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 61. HEMAGEN DIAGNOSTICS INC.: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Autoimmune Disease Diagnostics Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved